[Lab] SGN survo — VendorInvestigate came back 93.7% against a claimed 98.6%
Right, the API source question again, but with numbers this time. I have 4 data points over 12 weeks. The pattern is consistent enough that I do not think it is chance, and boring enough that nobody is going to screenshot it, which is usually a good sign. The thing I would flag for anyone new: the effect I am…
regulatory claims need a citation to the actual rule, not interpretation
Yeah, 503A and 503B are different regulatory animals.
Small correction: the trial was 17 weeks, not 32. Does not change your point but people will quote it.
Small correction: the trial was 15 weeks, not 37. Does not change your point but people will quote it.
telehealth prescriber models exist, pricing differs by state
[removed by moderator]
You have restated the marketing copy. What is the actual substance here.
API transparency is the question that separates good compounders from sketchy ones
the the UK situation is different from the US, different regulations
API transparency is the question that separates good compounders from sketchy ones
Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.
shortage list status is 503B, check the actual list
the 503A/503B distinction is load-bearing, do not blur it